DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine

被引:36
作者
Dalquen, P [1 ]
Kleiber, B [1 ]
Grilli, B [1 ]
Herzog, M [1 ]
Bubendorf, L [1 ]
Oberholzer, M [1 ]
机构
[1] Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland
来源
CANCER CYTOPATHOLOGY | 2002年 / 96卷 / 06期
关键词
urine; cytology; DNA image cytometry; fluorescence in situ hybridization; bladder carcinoma; transitional cell carcinoma;
D O I
10.1002/cncr.10881
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Cystoscopy and histologic examination remain the standard methods for initial tumor diagnosis and monitoring for early detection of recurrences, since the sensitivity of conventional urinary cytology for the detection of urothelial tumors in urinary specimens is low. DNA image cytometry (ICM) and fluorescence in situ hybridization (FISH) have been suggested as ancillary tools. The goal of the current study was to compare the diagnostic value of DNA image cytometry and FISH for the noninvasive detection of urothelial tumors in voided urine. METHODS. Cytospin preparations were prepared from voided urine collected prior to the resection of 26 noninvasive (pTa) and 11 invasive (pT1-2) tumors. Specimens from 14 patients with benign prostatic hyperplasia were used as negative controls. DNA ICM was performed using the AUTOCYTE(TM) cell analytical system on Feulgen-stained cytospin specimens. The commercially available UroVysion(TM) FISH multiprobe was used to analyze chromosomes 3, 7, and 17, and 9p21. RESULTS. The overall sensitivity of cytology improved from 24% to 54% and to 78% if supplemented by ICM or FISH, respectively. Image cytometry detected all invasive tumors (pT1-2), while FISH missed one; FISH identified 19 of 26 (73%) pTa tumors, while only 9 (35%) of these tumors were aneuploid by ICM. The results of ICM and FISH were concordant in 37 of 51 (72%) cases. CONCLUSIONS. The current study shows that both FISH and ICM can successfully be used as supplementary methods to detect the clinically most relevant group of invasive bladder carcinomas. However, UroVysion FISH is more sensitive in the detection of pTa tumors than ICM, as it recognizes individual chromosomal alterations that frequently prevail in urothelial tumors. (C) 2002 American Cancer Society.
引用
收藏
页码:374 / 379
页数:6
相关论文
共 35 条
[1]   IMAGE CYTOMETRIC DEOXYRIBONUCLEIC-ACID ANALYSIS OF URINE SPECIMENS AS AN ADJUNCT TO VISUAL CYTOLOGY IN THE DETECTION OF UROTHELIAL CELL-CARCINOMA [J].
AMBERSON, JB ;
LAINO, JP .
JOURNAL OF UROLOGY, 1993, 149 (01) :42-45
[2]  
BILLEREY C, 1993, WORLD J UROL, V11, P156
[3]   Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990 [J].
Black, RJ ;
Bray, F ;
Ferlay, J ;
Parkin, DM .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (07) :1075-1107
[4]   Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy [J].
Brown, MJA ;
Slezak, JM ;
Lieber, MM ;
Jenkins, RB .
MAYO CLINIC PROCEEDINGS, 1999, 74 (12) :1214-1220
[5]  
Bubendorf L, 2001, AM J CLIN PATHOL, V116, P79
[6]   CYTOLOGY, FLOW-CYTOMETRY, IMAGE-ANALYSIS, AND INTERPHASE CYTOGENETICS BY FLUORESCENCE IN-SITU HYBRIDIZATION IN THE DIAGNOSIS OF TRANSITIONAL-CELL CARCINOMA IN BLADDER WASHES - A COMPARATIVE-STUDY [J].
CAJULIS, RS ;
HAINES, GK ;
FRIASHIDVEGI, D ;
MCVARY, K ;
BACUS, JW .
DIAGNOSTIC CYTOPATHOLOGY, 1995, 13 (03) :214-223
[7]  
delaRoza GL, 1996, MODERN PATHOL, V9, P571
[8]   Flow cytometric DNA analysis and chromosomal aberrations in malignant glioblastomas [J].
Ehemann, V ;
Hashemi, B ;
Lange, A ;
Otto, HF .
CANCER LETTERS, 1999, 138 (1-2) :101-106
[9]   Bladder transitional cell carcinomas: A comparative study of washing and tumor bioptic samples by DNA flow cytometry and FISH analyses [J].
Eleuteri, P ;
Grollino, MG ;
Pomponi, D ;
Guaglianone, S ;
Gallucci, M ;
De Vita, R .
EUROPEAN UROLOGY, 2000, 37 (03) :275-280
[10]  
Farabegoli F, 2001, CYTOMETRY, V46, P50, DOI 10.1002/1097-0320(20010215)46:1<50::AID-CYTO1037>3.0.CO